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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.032Inﬂammasomes serve as an intracellular machinery to initiate inﬂammatory response to various danger
signals. The present study tested whether an inﬂammasome centered on nucleotide oligomerization
domain-like receptor protein 3 (NLRP3) triggers endothelial inﬂammatory response to adipokine visfatin,
a major injurious adipokine during obesity. NLRP3 inﬂammasome components were abundantly expressed
in cultured mouse microvascular endothelial cells, including NLRP3, apoptosis-associated speck-like
protein, and caspase-1. These NLRP3 inﬂammasome molecules could be aggregated to form an inﬂam-
masome complex on stimulation of visfatin, as shown by ﬂuorescence confocal microscopy and size
exclusion chromatography. Correspondingly, visfatin signiﬁcantly increased caspase-1 activity and IL-1b
release in microvascular endothelial cells, indicating an activation of NLRP3 inﬂammasomes. In animal
experiments, direct infusion of visfatin in mice with partially ligated left carotid artery were found to have
signiﬁcantly increased neointimal formation, which was correlated with increased NLRP3 inﬂammasome
formation and IL-1b production in the intima. Further, visfatin-induced neointimal formation, endo-
thelial inﬂammasome formation, and IL-1b production in mouse partially ligated left carotid artery were
abolished by caspase-1 inhibition, local delivery of apoptosis-associated speck-like protein shRNA or
deletion of the ASC gene. In conclusion, the formation and activation of NLRP3 inﬂammasomes by
adipokine visfatin may be an important initiating mechanism to turn on the endothelial inﬂammatory
response leading to arterial inﬂammation and endothelial dysfunction in mice during early stage obesity.
(Am J Pathol 2014, 184: 1617e1628; http://dx.doi.org/10.1016/j.ajpath.2014.01.032)Supported by the NIH grants HL-57244, HL-075316, DK54927, and
HL-091464 (P.-L.L.).
Disclosures: None declared.Obesity is amajor risk factor for cardiovascular disease and has
been strongly associated with endothelial dysfunction and
coronary atherosclerosis. Obese patients have signiﬁcantly
elevated morbidity and mortality due to coronary artery dis-
ease.1 However, weight loss can decrease cardiovascular risk,
improve endothelial function, and protect coronary arteries
from atherosclerotic injury. However, mechanisms underlying
obesity-associated coronary atherosclerotic injury and endo-
thelial dysfunction are not fully understood. Numerous studies
have reported a critical role of vascular inﬂammation in the
development of coronary atherosclerosis, which has been
characterized as an inﬂammatory disease.2e6 To date, the pre-
cisemechanism thatmediates the early inﬂammatory responses
of endothelial cells (ECs) during obesity remains unknown.
Recently, the inﬂammasome as an intracellular in-
ﬂammatory machinery has been reported to switch on thestigative Pathology.
.inﬂammatory response of tissues or organs to various
danger signals.7,8 Among different types of inﬂammasomes,
the nucleotide oligomerization domain (Nod)-like receptor
family pyrin domain containing 3 (NLRP3) inﬂammasome
is well characterized in a variety of mammalian cells,
especially as a receptor for endogenous danger signals such
as ATP, cholesterol crystal, b-amyloid, and monosodium
urate.2,9e14 The NLRP3 inﬂammasome is characteristic of a
proteolytic complex mainly composed of NLRP3, the
adaptor protein apoptosis-associated speck-like protein
(ASC), and caspase-1. On stimulation, NLRP3 inﬂamma-
somes oligomerize to form large multimolecular complexes
Xia et althat control the caspase-1 activity and subsequent bioactive
IL-1b production.10,15e18 More recently, NLRP3 inﬂam-
masomes have been implicated in the development of
obesity and insulin resistance.11 For example, the con-
sumption of a high-fat diet (HFD) has been considered as
critical contributor to type 2 diabetes, and NLRP3 inﬂam-
masome might be an important pathway of HFD mediating
insulin resistance leading to inﬂammation.19 These ﬁndings
led us to wonder whether activation of NLRP3 inﬂamma-
some is an initiating mechanism for obesity-induced endo-
thelial inﬂammatory responses.
Adipose tissue as an active metabolic tissue secretes multiple
metabolically important proteins known as ‘adipokines.’20,21
Visfatin is a newly identiﬁed adipokine and a major injurious
factor during obesity-associated diseases, including diabetes,22
carotid and coronary atherosclerosis,23,24 and chronic kidney
disease.25,26 Visfatin has also been considered as a pro-
inﬂammatory adipokine to promote endothelial inﬂammation
and injury.27,28 The present study was designed to test the hy-
pothesis that activation of NLRP3 inﬂammasomes is one of the
important mechanisms that mediate endothelial inﬂammatory
response to visfatin during early-stage obesity.We used a series
of molecular and physiological approaches both in vitro and
in vivo to test this hypothesis.
Materials and Methods
Cell Culture and Treatment
The mouse microvascular EC (MVEC; also known as estab-
lished murine microvascular EC) line was purchased from
ATCC (Manassas, VA). This cell line was originally isolated
from mouse hemangioendothelioma. These MVECs were
cultured in Dulbecco’s modiﬁed Eagle’s medium (Gibco,
Carlsbad, CA), supplemented with 10% fetal bovine serum
(Gibco) and 1% penicillinestreptomycin (Gibco) in humidi-
ﬁed95%air and5%CO2mixture at 37C.Cellswere passaged
by trypsinization (Trypsin/EDTA; Sigma, St. Louis, MO),
followed by dilution in Dulbecco’s modiﬁed Eagle’s medium
that contained 10% fetal bovine serum. Cells were used for
experiments between passages 6 and 13. Cells were treated
with 2 mg/mL visfatin (BioVision, Mountain View, CA) for
indicated hours. Because the optimum response of inﬂam-
masome activation was observed after 4-hour visfatin stimu-
lation, the same treatment was used in all experiments of the
present study if not otherwise mentioned. To inhibit caspase-1
activity, cells were pretreated with 1 mmol/L Z-WEHD-FMK
(WEHD; R&D Systems, Minneapolis, MN) for 30 minutes.
RNA Interference of ASC
siRNAs were commercially available (Qiagen, Valencia, CA).
The sequence for ASC siRNA is 50-AAGGCCGTGAGTTTC-
TACCT-30, which was conﬁrmed to be effective in silen-
cing ASC gene in different cells by the company. The
scrambled smRNA (50-AATTCTCCGAACGTGTCACGT-30)1618has been also conﬁrmed as nonsilencing double-stranded RNA
and was used as control in the present study. Transfection
of siRNA was performed with the siLentFect Lipid Reagent
(Bio-Rad, Hercules, CA) according to the manufacturer’s
instructions.
RT-PCR
Total RNA from cells was extracted with TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. One-microgram aliquots of total RNA from each
sample were reverse-transcribed into cDNA by using a ﬁrst-
strand cDNA synthesis kit (Bio-Rad). Equal amounts of the
reverse transcriptional products were subjected to PCR
ampliﬁcation on a Bio-Rad iCycler system (Bio-Rad). The
primers used in this study were synthesized by Operon
(Huntsville, AL), and the sequences were as follows: NLRP3
sense, 50-TACGGCCGTCTACGTCTTCT-30; NLRP3 anti-
sense, 50-CGCAGATCACACTCCTCAAA-30; ASC sense,
50-ACAGAAGTGGACGGAGTGCT-30; ASC antisense, 50-
CTCCAGGTCCATCACCAAGT-30; caspase-1 sense, 50-
CACAGCTCTGGAGATGGTGA-30; caspase-1 antisense,
50-TCTTTCAAGCTTGGGCACTT-30; and b-actin sense 50-
TCGCTGCGCTGGTCGTC-30; b-actin antisense 50-GGC-
CTCGTCACCCACATAGGA-30.
Confocal Microscopic Analysis
For confocal analysis of inﬂammasome molecules in MVECs,
cultured cells were grown on glass coverslips, stimulated or
unstimulated, and ﬁxed in 4%paraformaldehyde in PBS for 15
minutes. After being permeablized with 0.1% Triton X-100/
PBS and rinsedwith PBS, the cells were incubated overnight at
4C with goat anti-NLRP3 (1:200; Abcam, Cambridge, MA)
and rabbit anti-ASC (1:50; Enzo, PA), or rabbit antiecaspase-1
(1:100; Abcam). To colocalize inﬂammasome molecules
in the mouse coronary artery, double-immunoﬂuorescence
stainingwas performedwith frozen tissue slides.Afterﬁxation,
the slides were incubated overnight at 4C with goat
anti-NLRP3 (1:200) and rabbit anti-ASC (1:50) or with antie
caspase-1 (1:100). After washing, these slides probed with
primary antibodies were incubated with Alexa 488- or Alexa
555-labeled secondary antibodies for 1 hour at room temper-
ature. The slides were mounted and subjected to examinations
by using a confocal laser scanning microscope (Fluoview
FV1000; Olympus, Tokyo, Japan), with photos being taken,
and the colocalization of NLRP3 with ASC or caspase-1 was
analyzed by the Image Pro Plus version 6.0 software (Media
Cybernetics, Bethesda, MD). These summarized colocaliza-
tion efﬁciency data were expressed as Pearson correlation
coefﬁcient as we described previously.28
Immunocytochemical Analysis
For immunocytochemical analysis, MVECs grown on glass
coverslips were quickly washed by PBS and ﬁxed in 4%ajp.amjpathol.org - The American Journal of Pathology
Inﬂammasome Activation by Visfatinparaformaldehyde in PBS for 15 minutes. Then cells were
permeabilized by washing with a PBS-Tween 20 buffer
twice and followed by 1% bovine serum albumin blocking
for 30 minutes before the primary antibody incubation
(1:200). After 1 hour of incubation at room temperature,
the slides were washed and incubated with biotinylated
IgG secondary antibody (1:500) for 1 hour and then with
streptavidin-horseradish peroxidase for 30 minutes at
room temperature. After 1 minute of diaminobenzidine
staining, the slides were rinsed and counterstained with
hematoxylin. The slides were then mounted and observed
under a microscope.
Western Blot Analysis
Protein from cell lysate was run on a SDS-PAGE gel, trans-
ferred into polyvinylidene diﬂuoride membrane, and blocked.
Then the membrane was probed with primary antibodies
against NLRP3, ASC, or caspase-1 (1:500 dilution) overnight
at 4C, followed by incubation with horseradish-labeled IgG.
The immunoreactive bands were detected by chem-
iluminescence methods and visualized on Kodak Omat ﬁlm.
b-Actin was reprobed to serve as a loading control. The in-
tensity of the bands was quantiﬁed by densitometry with the
use of ImageJ software version 1.44p (NIH, Bethesda, MD).
SEC
After visfatin treatment, cells were homogenized with the
following protein extraction buffer: 20 mmol/L 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid-KOH (pH
7.5), 10 mmol/L KCl, 1.5 mmol/L MgCl2, 1 mmol/L Na
EDTA, 1 mmol/L Na EGTA, and 1  protease inhibitor
cocktail set I (Calbiochem, Gibbstown, NJ). Samples were
then centrifuged at 18,000  g for 10 minutes at 4C and
run on a Sepharose 6 size-exclusion chromatography (SEC)
column with the following buffer: 50 mmol/L Tris (pH 7.4),
150 mmol/L NaCl, 1% octylglucoside, and 1 protease
inhibitor cocktail. Fractions (200 mL) were collected, start-
ing at the void volume time. Five times sample buffer was
added directly to the fractions, heated at 95C for 5 minutes,
and then resolved in SDS-PAGE gels followed by Western
blot analysis. Protein standards were run on a column under
identical conditions, and the fractions were analyzed with
absorbance at 280 nm.
Caspase-1 Activity and IL-1b Production Assay
After visfatin treatment, cells were harvested and homoge-
nized to extract proteins for caspase-1 activity assay by
using a commercially available kit (Biovision). These data
were expressed as the fold change compared with control
cells. In addition, the cell supernatant was also collected to
measure the IL-1b production by a mouse IL-1b ELISA kit
(Bender Medsystems, Burlingame, CA) according to the
protocol described by the manufacturer.The American Journal of Pathology - ajp.amjpathol.orgESR Spectrometric Detection of O2

Electromagnetic spin resonance (ESR) detection of O2
 was
also performed as we described previously.28,29 In brief,
after visfatin treatment, MVECs were gently collected in
modiﬁed Krebs/HEPES buffer that contained 25 mmol/L
deferroximine (metal chelator). Approximately 1  106
MVECs were mixed with 1 mmol/L spin-trap compound,
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetrame-thyl-pyrro-
lidine, in the presence or absence of 100 U/mL poly-
ethylene glycol-conjugated superoxide dismutase. The cell
mixture loaded in glass capillaries was immediately
analyzed by ESR (Noxygen Science Transfer &Diagnostics
GmbH, Denzlingen, Germany) for production of O2
 at
each minute for 10 minutes. The superoxide dismutase-
inhibitable signals were normalized by protein concentra-
tion and compared among different experimental groups.
Partial Carotid Ligation and Osmotic Pump
Implantation
Eight-week-old male C57BL/6J wild-type and Asc/ mice
were used.12 All protocols were approved by the Institutional
Animal Care and Use Committee of Virginia Commonwealth
University. Partial carotid ligation surgery was performed as
previously reported by others.30,31 In brief, animals were
sedated with 2% isoﬂurane that was provided through a nose
cone. Next, a ventral midline incision of 4 to 5 mm was made
in the neck. With the use of blunt dissection, muscle layers
were separated with curved forceps to expose the left carotid
artery (LCA). Three of four branches of the LCA (left
external carotid, internal carotid, and occipital arteries) were
ligated by using a 6-0 silk suture. The superior thyroid artery
was left intact, providing the sole source for blood circula-
tion. The incision was then closed, and the animals were kept
on a heating pad until they gained consciousness. In the
visfatin infusion group, the osmotic pump (model 2002;
Alzet, Cupertino, CA) ﬁlled with 20 ng/kg per day of visfatin
was implanted subcutaneously, and the catheter was inserted
into the external jugular vein. In another group, mice were
injected intraperitoneally with WEHD, a caspase-1 inhibitor,
at a dosage of 1 mg/kg per day before implantation of the
visfatin pump. Fourteen days after partial ligation, animals
were sacriﬁced by cervical dislocation after the administra-
tion of anesthesia. Blood samples were collected; LCAs and
right carotid arteries were then harvested for immunohisto-
chemistry, dual ﬂuorescence staining, and confocal analysis.
Gene Transfection in Mouse Carotid Artery by
Ultrasound-Microbubble Technique
Plasmid DNA or shRNA (200 mg) was freshly prepared in
300 mL of saline with 20% microbubble (Optison; GE
Healthcare, Chalfont St. Giles, UK). After anesthesia by 2%
of isoﬂurane, the LCA was exposed by a midline incision,
and then the left femoral vein was exposed as well. The1619
Figure 1 Visfatin increases NLRP3 inﬂammasome formation in MVECs.
A: RT-PCR gel images show the expression of NLRP3, ASC, and caspase-1 in
cultured MVECs and in carotid arteries. B: Western blot analysis shows
protein expression of NLRP3, ASC, and caspase-1 in MVECs. C: Represen-
tative confocal ﬂuorescence images depict the effect of visfatin on the
colocalization of NLRP3 with ASC or caspase-1. D: Summarized data show
the colocalization efﬁciency of NLRP3 with ASC (black bars) or NLRP3 with
caspase-1 (gray bars). Data are expressed as means  SEM; n Z 6 (A, B,
and D). *P < 0.05 versus untreated control group. Casp-1, caspase-1.
Xia et alplasmid mixture was directly injected into the femoral vein.
Simultaneously, transthoracic ultrasound insonation (Soni-
tron 2000; Rich-Mar, Inola, OK) was performed through a
6-mm diameter probe with an input frequency of 1 MHz, an
output intensity of 1.0 to 2.0 W/cm2, a pulse duty ratio of
10% to 50% for a total of 180 seconds with 30-second in-
tervals. After closing the wound, the mouse remained on the
heating board until recovery.
In Vivo Imaging of Gene Expression in Mouse Carotid
Artery
To monitor the efﬁciency of gene expression through somatic
plasmid transfection, mice were anesthetized with 0.7% to
1.5% isoﬂurane, and an aqueous solution of 150 mg/kg lucif-
erin was intraperitoneally injected 5 minutes before imaging.
The anesthetized mice were imaged with the IVIS200 in vivo
imaging system (Xenogen, Alameda, CA). Photons emitted
from luciferase-expressing cells within the animal body and
transmitted through tissue layers were quantiﬁed over a
deﬁned period of time that ranged up to 5 minutes by using the
software programLiving Image (Xenogen) as an overlay on an
Igor program version 2.6 (WaveMetrics, Lake Oswego, OR).
Animals
C57BL/6J mice (8 weeks of age, male; The Jackson Labo-
ratory, Bar Harbor, ME) were fed a normal diet (ND) or a
HFD (Dyets Inc., Bethlehem, PA) for 10 weeks to induce
obesity as we described previously.32 In another group, mice
were injected intraperitoneally with WEHD, a caspase-1 in-
hibitor, at a dosage of 1 mg/kg per day before the treatment
with HFD. At the end point, blood samples were collected,
these mice were sacriﬁced, and heart tissues were harvested
for dual ﬂuorescence staining and confocal analysis. All
protocols were approved by the Institutional Animal Care
and Use Committee of Virginia Commonwealth University.
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded heart tissue sections
(4 mm) were stained with rabbit anti-visfatin (1:50; Abcam)
and goat anti-IL1b (1:50; R&D Systems) overnight at 4C
after a 20-minute wash with 3% H2O2 and 30-minute
blocking with serum. The slides were sequentially treated
with CHEMICON IHC Select horseradish peroxidase/dia-
minobenzidine Kit (EMD Millipore, Billerica, MA) accord-
ing to the protocol described by the manufacturer. Finally, the
slides were counterstained with hematoxylin. Negative con-
trols were prepared by leaving out the primary antibodies.
Statistical Analysis
Data are presented as means  SEM. Signiﬁcant differences
between and within multiple groups were examined with
analysis of variance for repeated measures, followed by1620 ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Distribution of inﬂammasome components after size-exclusion
chromatography in MVECs. A: Elution proﬁle of proteins from both standard
andMVEC samples at an absorbance of 280 nm.Molecular mass of the samples
were determined by comparison to a gel ﬁltration standard. B: Western blot
analysis of protein fractions obtained from untreated, visfatin, Asc siRNA-
treated MVECs probed with anti-NLRP3, ASC, and caspase-1 antibodies. C:
Data summary shows the band intensities measured from the inﬂammasome
complex fractions (fractions 7 to 21) of NLRP3 (black bars), ASC (light gray
bars), and caspase-1 (dark gray bars). Data are expressed as means  SEM;
nZ 6 (C). *P< 0.05 versus Ctrl group; yP< 0.05 versus Scrþ visfatin group.
ASCsi, ASC siRNA; Ctrl, control; Scr, scramble.
Inﬂammasome Activation by VisfatinDuncan’s multiple-range test. P < 0.05 was considered
statistically signiﬁcant.
Results
Visfatin Induces the NLRP3 Inﬂammasome Formation
in MVECs
With the use of cultured mouse MVECs, we ﬁrst character-
ized the formation of NLRP3 inﬂammasomes. RT-PCR
analysis detected NLRP3, ASC, and caspase-1 mRNAs in
MVECs (Figure 1A). The protein expression of these
inﬂammasome components were conﬁrmed by Western blot
analysis (Figure 1B).
We next analyzed the inﬂammasome formation inMVECs
by SEC and confocal microscopy. As shown in Figure 1C,
the colocalization of NLRP3 with ASC or caspase-1 was
increased in a time-dependent manner, indicating the ag-
gregation or assembly of these inﬂammasome molecules.
The Pearson correlation coefﬁcient of NLRP3 with ASC or
caspase-1 was summarized to represent the colocalization
efﬁciency (Figure 1D). Such colocalization of NLRP3 mol-
ecules suggested the formation of NLRP3 inﬂammasomes in
MVECs on visfatin stimulation. The maximum colocaliza-
tion level was observed after 4-hour treatment of visfatin in
MVECs; therefore, the same visfatin treatment was used in
the rest of experiments if not otherwise mentioned.
To further conﬁrm the NLRP3 inﬂammasome formation in
response to visfatin, we next analyzed the assembly ofNLRP3
inﬂammasome proteins as a complex in MVECs by SEC.
Total proteins fromMVECs were eluted through a Sepharose
6 SEC column, and all of the proteins were separated into
different fractions according to their size andwere detected by
Western blot analysis (Figure 2A). It was observed that the
speciﬁc bands for NLRP3, ASC, and caspase-1 were located
in the low-molecular weight fractions under control condi-
tions. However, on stimulation of visfatin for 4 hours, these
bands speciﬁc to inﬂammasome components migrated into
high-molecular weight factions, which were termed inﬂam-
masome fractions (Figure 2B); however, such migration was
not found in cells transfected with ASC siRNA, indicating the
aggregation or assembly of these inﬂammasome molecules,
namely, the formation of NLRP3 inﬂammasome complex in
MVECs. Moreover, visfatin treatment increased total protein
expression of inﬂammasome components inMVECs. OnAsc
siRNA transfection before the addition of visfatin, a clear
decrease in large inﬂammasome protein complex was
observed in the high-molecular weight fractions. The in-
tensity of these bands was quantiﬁed by ImageJ software and
summarized (Figure 2C).
Visfatin Increases Caspase-1 Activity and IL-1b
Production in MVECs
Visfatin signiﬁcantly increased expression of active caspase-1
(20 kDa), indicating increased cleavage of proecaspase-1 intoThe American Journal of Pathology - ajp.amjpathol.orgbioactive caspase-1 (Figure 3, A and B). We also noticed that
visfatin did not decrease protein expression of proe
caspase-1, which could be due to up-regulation of proe
caspase-1 protein synthesis. Consistently, visfatin signiﬁcantly1621
Figure 3 Visfatin activates caspase-1 and IL-1b production in MVECs. A: Western blot analysis shows the effect of visfatin on proecaspase-1 and active
caspase-1 expression. B: Summary of Western blot results. Summary of data for relative caspase-1 activity (C) and relative IL-1b production (D) compared with
control. Data are expressed as means  SEM; n Z 6 (C and D). *P < 0.05 versus control group.
Xia et alincreased caspase-1 activity (Figure 3C) and IL-1b release
(Figure 3D) in MVECs. However, visfatin-induced caspase-1
activity and IL-1b production were attenuated by anti-visfatin
antibody (Supplemental Figure S1). Collectively, these results
indicated that visfatin induced formation and activation of the
NLRP3 inﬂammasomes in MVECs.
Effects of ASC Gene Silencing or Caspase-1 Inhibition
on Visfatin-Induced Inﬂammasome Activation
Knockdown of ASC mRNA level by ASC siRNA silencing in
MVECs markedly inhibited visfatin-induced colocalization of
NLRP3 with ASC or caspase-1 (Figure 4, A and B). Further-
more, visfatin-induced colocalization of NLRP3 with caspase-
1 was attenuated in Asc/ mice ECs (Supplemental
Figure S2). Consistent with these ﬁndings, ASC gene
silencing or blockade of caspase-1 activity by using WEHD
almost completely blocked visfatin-induced increases in
caspase-1 activity (Figure 4C) and IL-1b production
(Figure 4D) inMVECs. In addition, visfatin-induced caspase-1
activity and IL-1b production in NLRP3 shRNA transfected
MVECs (Supplemental Figure S3). Interestingly, 6 mg/mL
adiponectin, the most abundant adipocyte protein with anti-
inﬂammatory properties, had no effect on inﬂammasome for-
mation, caspase-1 activity, and IL-1b production (Figure 4,
AeD), indicating that this protective adipokine did not induce
inﬂammasome formation and activation in MVECs.
Visfatin-Induced O2
 Production in MVECs
Visfatin treatment signiﬁcantly increased O2
 production
compared with control cells (Figure 5A). However, prior
treatment with 1 mmol/L methyl-b-cyclodextrin [MCD;
membrane raft (MR)disruptor] for 20minutes and0.1mmol/L
Tempol [reactive oxygen species (ROS) scavenger] for 20
minutes signiﬁcantly attenuated the visfatin-induced O2

production. In contrast, thioredoxin-interacting protein
(TXNIP) siRNA transfection did not alter O2
 production
induced by visfatin. These data suggested that visfatin acti-
vation of the NLRP3 inﬂammasomes might be through the
MR-derived ROS production. Further, we examined whether1622the MR redox signaling pathway was involved in visfatin-
induced NLRP3 inﬂammasome activation. We determined
caspase-1 activity and IL-1b production in MVECs with or
without prior treatment ofMCD, Tempol, and TXNIP siRNA.
Visfatin treatment signiﬁcantly increased caspase-1 activity
and IL-1b production comparedwith control cells (Figure 5, B
and C). However, prior treatment with MCD, Tempol, and
TXNIP siRNA signiﬁcantly attenuated visfatin-induced cas-
pase-1 activity and IL-1b production.
Efﬁciency of in Vivo Local Transfection of ASC shRNA
into the Carotid Artery
We used an IVIS in vivo molecular imaging system to detect
the expression of cotransfected luciferase gene, which en-
sures an efﬁcient delivery of target gene into the mouse
carotid artery (Figure 6A). The luciferase reporter gene was
monitored in the carotid artery of the living mouse after the
injection of plasmid mixed with microbubbles under ultra-
sound force. Starting on day 3, the expression of luciferase
gene persisted for 2 weeks. As shown in an isolated carotid
artery at day 6 after gene delivery, the reporter gene lucif-
erase was speciﬁcally expressed on the LCA but not on the
right carotid artery (Figure 6B). Immunohistochemical an-
alyses indicated that ASC expression in the carotid artery
was effectively inhibited even after 2 weeks of gene trans-
fection (Figure 6C).
Morphological Analysis in PLCA of Mice with Visfatin
Infusion
We next tested whether visfatin-induced inﬂammasome
activation in ECs might affect neointimal expansion in mice
with partially ligated carotid artery (PLCA). It was reported
that IL-1b, a proinﬂammatory cytokine (an inﬂammasome
product), plays a key role in the formation of neointimal
lesion after PLCA in mice model33 and that IL-1b was
robustly increased in porcine coronary arteries after balloon
injury.33,34 Hence, we chose the PLCA model for in vivo
studies. Morphological analysis indicated that visfatin
infusion markedly increased the neointimal formation andajp.amjpathol.org - The American Journal of Pathology
Figure 4 ASC gene silencing abolishes visfatin-induced NLRP3
inﬂammasome formation and activation in MVECs. A: Representative
confocal ﬂuorescence images show the colocalization of NLRP3 with ASC or
NLRP3 with caspase-1. B: Data summary shows colocalization coefﬁciency
of NLRP3 with ASC or caspase-1. Data summary shows relative caspase-1
activity (C) and relative IL-1b production (D) compared with control.
Data are expressed as means  SEM; n Z 6. *P < 0.05 versus untreated
control group; yP < 0.05 (Scr þ Visfatin versus ASCsi þ Visfatin or visfatin
versus WEHD þ Visfatin). ADP, adiponectin; ASC si, Asc siRNA; ASCsi þ
visfatin, cells were transfected with ASC siRNA and then stimulated with
visfatin; Casp-1, caspase-1; Scr þ visfatin, cells were transfected with
scramble RNA and then stimulated with visfatin; WEHD þ visfatin, cells
were pretreated with caspase-1 inhibitor WEHD and then stimulated with
visfatin.
Inﬂammasome Activation by Visfatin
The American Journal of Pathology - ajp.amjpathol.orgintima/media ratio in the PLCA model compared with
vehicle-infused control mice (Figure 7, A and B). However,
such visfatin-induced neointimal formation and increased
intima/media ratio was signiﬁcantly reduced by caspase-1
inhibitor WEHD, local carotid transfection of ASC
shRNA, or in Asc/ mice (Figure 7, A and B). Further, we
tested whether such damage was directly induced by visfatin
by immunohistochemical analysis and detected the visfatin
expression in arteries. Visfatin penetrated into the intima
section during infusion (Figure 7, C and D). This might
directly switch on the intracellular inﬂammatory response,
leading to further damage.Figure 5 Effect of inhibition of MR-Redox signaling and TXNIP on
visfatin-induced NLRP3 inﬂammasomes formation in MVECs. Data sum-
mary shows O2
 production (A), caspase-1 activity (B), and IL-1b
production (C) in MVECs with or without stimulation of visfatin. Data
are expressed as means  SEM; n Z 6. *P < 0.05 versus Ctrl group;
yP < 0.05 versus visfatin group. MCD, methyl-b-cyclodextrin; Scram,
scrambled siRNA; Tempo, 4-hydroxyl-tetramethylpiperidin-oxyl; TXNIP
si, TXNIP siRNA.
1623
Figure 6 In vivo and in vitro determination of ASC shRNA transfection
efﬁciency in the carotid artery. ASC shRNA (ASC sh) and luciferase cDNA plas-
mids were locally delivered into the LCA by using an ultrasound microbubble
method. A: Daily imaging conﬁrmation of gene transfection by detection of
cotransfected luciferase gene expression by using an IVIS in vivo molecular
imaging system. B: Localization of luciferase gene expression in isolated ca-
rotid arteries at day 6 after gene delivery. C: Immunohistochemical analysis of
ASC expression in carotid arteries from mice with ASC shRNA transfection and
partial ligation at the left artery for 2 weeks of visfatin administration. LCA, left
carotid artery; RCA, right carotid artery; Scra, scrambled siRNA.
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1624Inﬂammasome Formation and Activation in PLCA with
Visfatin Infusion
Colocalization of NLRP3 with ASC or caspase-1 was barely
observed in vehicle-infused control mice with PLCA
(Figure 8, A and C). However, when these mice with PLCA
were infused with visfatin, colocalization of NLRP3 with
ASC or caspase-1 was signiﬁcantly increased as indicated
by intense yellow spots or patches in the intima of the
arterial wall. The Pearson correlation coefﬁcient of NLRP3
with ASC or caspase-1 showed the quantitative colocaliza-
tion of NLRP3 with ASC (Figure 8B) or NLRP3 with
caspase-1 (Figure 8D) in carotid arteries of mice. The
colocalization of NLRP3 with ASC or caspase-1 suggests
the formation of inﬂammasomes in the endothelium of
PLCA in mice with visfatin administration. Moreover, ASC
shRNA transfection or ASC gene deletion substantially
suppressed and caspase-1 inhibition markedly attenuated the
visfatin-induced colocalization of NLRP3 with ASC or
caspase-1 in carotid arteries, suggesting that genetic or
pharmacological interventions that target inﬂammasome
components could block the visfatin-induced inﬂammasome
formation in the endothelium of PLCA.
Immunohistochemical studies indicated that no IL-1b
expression was detected in PLCA from vehicle-infused
mice (Figure 9, A and B). However, visfatin-infused mice
had a marked increase in IL-1b expression in the intima
layer of PLCA. Such visfatin-induced IL-1b expression in
the intima was abolished by the caspase-1 inhibitor
WEHD, local carotid transfection of ASC shRNA, or ASC
gene deletion.
Increased Inﬂammasome Formation and Activation in
Obese Mice
In addition, we tested the role of NLRP3 inﬂammasomes in
mice fed a HFD. We observed that a HFD signiﬁcantly
increased the plasma visfatin concentration compared with
control mice (Supplemental Figure S4). WEHD treatment
had no effect on plasma visfatin concentration. With the use
of confocal microscopy, we observed that, under control
condition, NLRP3 barely colocalized with caspase-1 in ND-
fed mice, whereas in HFD-fed mice, we observed increased
colocalization of NLRP3 with caspase-1 as indicated by
intense yellow spots or patches in the intima of the arterial
wall. Such colocalization suggests the formation of NLRP3
inﬂammasomes in coronary arterial endothelium in mice.
Importantly, caspase-1 inhibition attenuated the HFD-
induced colocalization of NLRP3 with caspase-1 in carotid
arteries. Further, immunohistochemical analysis indicated
that IL-1b expression was barely detected in coronary arteries
of ND-fed mice. HFD markedly increased the IL-1b
expression in endothelium layer of coronary arteries
(increased brown staining in the intima). However, caspase-1
inhibition signiﬁcantly attenuated the HFD-induced increase
in IL-1b expression (Supplemental Figure S4).ajp.amjpathol.org - The American Journal of Pathology
Figure 7 Visfatin infusion enhances neo-
intimal formation in PLCA. WT mice were intrave-
nously infused by vehicle or visfatin and were
treated with vehicle (Ctrl) or caspase-1 inhibitor
WEHD or transfected with ASC shRNA for 2 weeks
after the partial ligation of the left artery. ASC KO
mice were intravenously infused by vehicle or vis-
fatin for 2 weeks after partial ligation of the left
artery. A: Photomicrographs of PLCA 2 weeks after
visfatin i.v. infusion (H&E staining). AOI: the
media area (black arrowheads) and the intima
area (white arrowheads). B: Quantitative analysis
of vascular lesions in PLCA represented by the ratio
between intima and media. C: Representative
immunohistochemical images of visfatin expres-
sion in endothelial layer of PLCA. D: Quantitative
analysis of positive stain of visfatin in intima
section. Data are expressed as means  SEM;
n Z 6 mice per group. *P < 0.05 versus vehicle
control group; yP < 0.05 versus visfatin group.
Scale bars: 50 mm (A, 100 images); 20 mm (A,
AOI images); 5 mm (C). AOI, area of interest; Ctrl,
control; KO, knockout; Vehi, vehicle; Visf, visfatin;
WT, wild-type.
Inﬂammasome Activation by VisfatinDiscussion
The present study indicated that visfatin induced formation
and activation of NLRP3 inﬂammasomes both in vitro and
in vivo. In cultured MVECs, visfatin induced aggregation of
NLRP3 inﬂammasome components, activation of caspase-1,
and production of IL-1b. Our animal experiments demon-
strated that visfatin infusion signiﬁcantly increased inﬂam-
masome formation, caspase-1 activity, and IL-1b production
in PLCAs, which were almost completely blocked by
caspase-1 inhibition or Asc gene inhibition. These results
suggest that the formation and activation of NLRP3 inﬂam-
masomes by visfatin may be an important initiating mecha-
nism to turn on the endothelial inﬂammatory response,
leading to carotid inﬂammation and endothelial dysfunction
during obesity.
Visfatin, an adipokine involved in pro-inﬂammatory re-
sponses,27 has been implicated in a wide range of inﬂam-
matory disorders in obesity and associated cardiovascular
diseases.23,24,35 Visfatin has been demonstrated as contrib-
utor to endothelial dysfunction through the up-regulation of
NF-kB activation in ECs,36 which is an important step for
NLRP3 inﬂammasome-mediated IL-1b production.27,37
NLRP3 inﬂammasome activation is known to cause
caspase-1 activation and cleavage of proeIL-1b and pro-18
into their bioactive form, namely, IL-1b or IL-18. Therefore,
the present study explored whether it is indeed involved in
visfatin-induced IL-1b production and inﬂammatory re-
sponses. We ﬁrst characterized the expression and activation
of this inﬂammasome complex and found mRNA and protein
expression of the three NLRP3 inﬂammasome molecules,The American Journal of Pathology - ajp.amjpathol.orgnamely NLRP3, ASC, and caspase-1, in MVECs. Impor-
tantly, visfatin stimulation induced the formation of NLRP3
inﬂammasomes in MVECs as shown by colocalization of
NLRP3 with ASC or NLRP3 with caspase-1. Because
inﬂammasomes form multimolecular oligomers with high-
molecular weight, inﬂammasomes can be isolated and
detected by SEC with Western blot analysis as described.38
With the use of these approaches, we found that visfatin
increased expression of NLRP3, ASC, and caspase-1 in high-
molecular weight fractions (>600 kDa), which conﬁrms the
assembly of inﬂammasomes in MVECs. Moreover,
biochemical analysis demonstrated that visfatin increased the
caspase-1 activity and IL-1b production in MVECs. Thus,
these results clearly show that the NLRP3 inﬂammasomes are
present and functioning in ECs and that visfatin stimulation
can lead to their activation. Consistently, recent studies also
demonstrated the activation of NLRP3 inﬂammasomes in
ECs under different conditions such as lipopolysaccharide
and interferon-g stimulation, acetaminophen treatment, or
hemorrhagic shock.39e42 Although these reports showed that
NLRP3 and other inﬂammasomes can be activated in ECs
under different pathological conditions, the results from the
present study provide the ﬁrst experimental evidence that
adipokine visfatin can activate NLRP3 inﬂammasomes in
ECs, which may be an important pathogenic mechanism
responsible for endothelial inﬂammation during obesity.
The present study further examined the mechanism of
action of visfatin-induced NLRP3 inﬂammasome activation
in MVECs. Our recent studies demonstrated that visfatin is
an important factor to activate NADPH oxidase-derived
ROS production through MR redox signaling platforms in1625
Figure 9 Visfatin increases the IL-1b production in PLCA. A: Repre-
sentative immunohistochemical images show IL-1b-positive stains in the
intima of PLCA. B: Quantitative analysis of positive stain of IL-1b in intima
section. Data are expressed as means  SEM; n Z 6 mice per group.
*P < 0.05 versus vehicle control group; yP < 0.05 versus visfatin group.
Scale bar Z 10 mm. Ctrl, control; KO, knockout; Vehi, vehicle; WT,
wild-type.
Figure 8 Visfatin induces the NLRP3 inﬂammasome formation in PLCA.
Representative confocal ﬂuorescence images show the colocalization of
NLRP3 with ASC (A) or caspase-1 (C) in the intima of PLCA. Data summary
shows the colocalization efﬁciency of NLRP3 with ASC (B) or caspase-1 (D).
Data are expressed as means  SEM; n Z 6 mice per group. *P < 0.05
versus vehicle control group; yP < 0.05 versus visfatin group. Scale bars: 10
mm (A and C). Ctrl, control; KO, knockout; PCC, Pearson correlation coef-
ﬁcient; Vehi, vehicle; WT, wild-type.
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1626ECs.28,29 It has been proposed that ROS act on a target
upstream of the NLRP3 inﬂammasome and indirectly cause
its activation.4345 However, the pathway that links ROS to
the inﬂammasome remains largely unknown. A recent study
showed that NLRP3 interaction with TXNIP whereby
inﬂammasome activators such as uric acid crystals induced
the dissociation of TXNIP from thioredoxin in a ROS-
sensitive manner and allowed it to bind NLRP3.46 In the
present study, we conﬁrmed that visfatin-induced ROS
production in MVECs, which was blocked by disrupting
MR redox signaling platforms (Figure 5A). Further, we
demonstrated that visfatin-induced caspase-1 activation and
IL-1b production were blocked by MR redox platform
disruption, ROS scavenging, or TXNIP gene silencing
(Figure 5, B and C). Thus, our data suggest that MR redox
signaling platform-derived ROS could be an important
mechanism to mediate visfatin-induced NLRP3 inﬂamma-
some activation in ECs via ROS-dependent release of
TXNIP and consequent TXNIP-NLRP3 interaction.
To further explore the role of NLRP3 inﬂammasomes in
mediating the action of visfatin in vivo, we locally modu-
lated gene expression of ASC in mouse carotid artery andajp.amjpathol.org - The American Journal of Pathology
Inﬂammasome Activation by Visfatinobserved changes in NLRP3 inﬂammasome colocalization
in PLCA with visfatin infusion. To reach this goal, we
combined an ultrasound technique and microbubble wrap-
ping to introduce plasmids into coronary vascular beds.
Several recent reports from our laboratory and by others
have shown that the ultrasound-microbubble system is an
effective method to deliver plasmids into cells of different
organs in vivo with a transfection rate >90%.47e50 Com-
bination of the ultrasound technique and microbubble
wrapping for introduction of plasmids greatly enhances
transgene expression with a 300-fold increase over naked
DNA alone without toxicity.48,50 The present study by using
in vivo molecular imaging demonstrated that plasmids (ASC
shRNA plasmids cotransfected with luciferase cDNA
plasmid) were successfully delivered into the LCA and
cotransfected luciferase expression persisted for up to 2
weeks. Such local gene silencing efﬁciently blocked ASC
expression in PLCA (Figure 6C). However, the local gene
silencing in mouse carotid artery had trivial or insigniﬁcant
decreases in visfatin expression levels in intima of visfatin-
infused PLCA (Figure 7D), suggesting that inhibition of
ASC expression by this local gene silencing is only effective
and limited to PLCA.
Although the strategies used to inhibit Asc in mice were
not endothelial speciﬁc, confocal ﬂuorescence microscopy
and immunohistochemical analysis revealed that such local
Asc gene silencing or Asc gene deletion substantially
abolished the visfatin-induced NLRP3 inﬂammasome for-
mation and IL-1b production in the endothelium of PLCA.
Inhibition of caspase-1 activity also markedly attenuated
inﬂammasome formation and IL-1b production in the
endothelium of PLCA. Taken together, our data provided
strong in vivo evidence that visfatin is an effective
inﬂammasome activator that leads to local inﬂammation in
the vasculature.
The present study further demonstrated that visfatin
enhanced the neointimal formation in PLCA, which was
blocked by local silencing of Asc gene or caspase-1 in-
hibition in the carotid artery. These data imply that
visfatin-induced endothelial inﬂammasome activation may
play a crucial role in initiation of endothelial dysfunction
and vascular injury. The present study did not aim to
deﬁne the precise mechanism of how visfatin-induced
NLRP3 inﬂammasome activation leads to endothelial
dysfunction or injury. It should be noted that visfatin
could also be up-regulated by IL-1b.51,52 In this regard, it
is possible that elevation of plasma visfatin during obesity
may initiate NLRP3 inﬂammasome activation in ECs to
release a small amount of IL-1b. This small amount of
IL-1b could then function in a paracrine or autocrine
fashion to increase massive visfatin expression in the
vasculature, which may result in a vicious cycle that am-
pliﬁes the inﬂammasome-mediated responses that lead to
endothelial dysfunction or injury. Targeting this visfatin-
inﬂammasome machinery at the stage of its assembling
or activation may be a novel therapeutic strategy toThe American Journal of Pathology - ajp.amjpathol.orgprevent the development of endothelial dysfunction or
injury during obesity.
In summary, the present study revealed a new triggering
mechanism of visfatin-induced inﬂammation that is charac-
terized by the formation and activation of NLRP3 inﬂam-
masomes in ECs in vitro and in vivo. This activation of
NLRP3 inﬂammasomes may represent a novel early event
that leads to endothelial dysfunction and injury, initiating
atherosclerosis during obesity.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2014.01.032.
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